查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085840

免疫球蛋白產品市場：依產品類型、原料、給藥途徑及應用分類－2026-2032年全球市場預測

Immunoglobulin Product Market by Product Type, Source, Route Of Administration, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫球蛋白產品市場將成長至 502.9 億美元，複合年成長率為 13.04%。

主要市場統計數據
基準年 2025 213.1億美元
預計年份：2026年 240億美元
預測年份 2032 502.9億美元
複合年成長率 (%) 13.04%

免疫球蛋白製劑是血漿衍生的生物製藥，用於補充或調節免疫介導疾病患者或有感染疾病族群的抗體。此類製劑包括靜脈注射免疫球蛋白（IVIG）、皮下注射免疫球蛋白（SCIG）以及用於治療原發性免疫力缺乏缺陷、慢性脫髓鞘多發性神經炎、免疫性血小板減少性疾病、多灶性運動神經病變、川崎病和某些次發性免疫力缺乏神經病變的特殊製劑。

免疫球蛋白產品市場受到以下因素的影響：免疫疾病診斷數量的增加、在神經病學和血液病學領域應用範圍的擴大，以及與人類血漿採集、分離能力、病毒安全性檢測、法規核准和低溫運輸配送相關的持續供應限制。對於行業領導企業，競爭優勢取決於可靠的血漿供應、值得信賴的生產品質、便捷的給藥方式、可追溯性以及保險公司認可的臨床價值證據。

免疫球蛋白領域的變革性變化

免疫球蛋白產品的市場模式正從以醫院為中心的靜脈注射免疫球蛋白（IVIG）治療模式轉向更靈活的照護模式，包括居家輸注和皮下注射免疫球蛋白（SCIG）的自我給藥。這一轉變得益於臨床實踐的趨勢，即強調減輕輸液中心的負擔、穩定血清IgG水平、降低部分患者的全身輸注相關反應，以及在醫學允許的範圍內提高患者的自主性。

人工智慧（AI）的累積影響

人工智慧 (AI) 正開始影響免疫球蛋白產品的整個價值鏈。在血漿業務中，AI 驅動的分析可以改善捐血者預約安排、預測採集量、識別營運瓶頸、支援合規性監控，並增強受監管捐血網路的可追溯性。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

北美仍然是免疫球蛋白產品需求和血漿供應的中心樞紐。美國作為這項樞紐的核心，擁有完善的血漿採集基礎設施、高度專業化的醫療服務以及免疫學、神經病學和血液學領域的高利用率。加拿大則採用更集中的血液和血漿管理模式，將供應規劃、全國協調、國內採集策略以及對進口的依賴程度視為關鍵的政策考量。

來自主要區域組織的見解：東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約

在東協市場，免疫學和神經病學醫療服務的重要性日益凸顯，但高所得醫療體系與保險報銷有限、專科醫生資源匱乏、血漿衍生療法預算不足的市場之間，在產品獲取方面存在顯著差距。海灣合作理事會（GCC）地區的特點是醫院投資力道大、對先進生物製藥的需求旺盛，且擁有集中採購系統。如果供應合約、核准流程和物流能力到位，這些優勢可以加快產品取得速度。

主要國家概況：美國、加拿大、墨西哥、巴西、歐洲、中國、印度、日本、澳洲、韓國

美國是免疫球蛋白產品市場最具影響力的國家，這得益於其龐大的確診患者群體、完善的靜脈輸液治療體系、廣泛的支付管道以及無與倫比的血漿採集規模。加拿大則專注於國家血液系統的准入管理和協調，而墨西哥正在拓展其專科醫療保健體系，但仍對價格、報銷差異、產品核准和公共採購趨勢保持敏感。

為行業領導者提供的實用建議

產業領導者應優先考慮血漿供應的穩定性，具體措施包括：拓展捐血中心網路、加強長期採血夥伴關係、提高捐血者留存率，以及投資血漿分離能力和生產冗餘系統。在供應緊張的市場環境下，供應的連續性既是核心的商業性差異化因素，也是保障病人安全的責任。

調查方法

本執行摘要採用二手調查方法，以公開的監管、臨床和產業資訊資訊來源編寫而成。相關資訊來源包括處方資訊、FDA和EMA等監管機構的指導意見、臨床指南、血液和血漿政策文件、醫療保健取得報告、藥物警戒參考資料以及關於免疫球蛋白使用的同行評審文獻。

結論

免疫球蛋白製劑仍將是治療免疫性疾病、神經系統疾病、血液系統疾病和發炎性疾病的重要手段。診斷技術的進步、臨床適應症的確立、治療路徑的擴展以及患者對靈活給藥方式的偏好，都支撐了市場對免疫球蛋白的需求；然而，血漿採集、分離過程耗時、品質控制以及生物製藥生產等實際限制因素，仍然制約著免疫球蛋白的供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 免疫球蛋白產品市場：依產品類型分類

  • 高免疫球蛋白
  • 標準免疫球蛋白

第8章：免疫球蛋白產品市場：依來源分類

  • 人類血漿庫
  • 重組

第9章：免疫球蛋白產品市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 皮下

第10章：免疫球蛋白產品市場：依應用分類

  • 血液疾病
    • 溶血性貧血
    • 特發性血小板減少紫斑症
  • 感染疾病
    • 甲型肝炎
    • 德國麻疹
    • 水痘
  • 神經病變
    • 慢性脫髓鞘多發性神經炎
    • Guillain-Barré二氏症候群
    • 重症肌無力
  • 原發性免疫力缺乏
    • 泛變異免疫力缺乏
    • 嚴重聯合免疫力缺乏
    • X連鎖無丙種球蛋白血症

第11章：免疫球蛋白產品市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 免疫球蛋白產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：免疫球蛋白產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • ADMA Biologics, Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Limited
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • Green Cross Corporation
  • Grifols, SA
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • PharmaSwiss SA
  • Prothya Biosolutions BV
  • Reliance Life Sciences Pvt. Ltd.
  • Sanquin Plasma Products BV
  • Shanghai RAAS Blood Products Co., Ltd.
  • SK Plasma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-43127F7279C5

The Immunoglobulin Product Market is projected to grow by USD 50.29 billion at a CAGR of 13.04% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.31 billion
Estimated Year [2026] USD 24.00 billion
Forecast Year [2032] USD 50.29 billion
CAGR (%) 13.04%

Immunoglobulin products are plasma-derived biologic therapies used to replace or modulate antibodies in patients with immune-mediated and infection-risk conditions. The category includes intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and specialty formulations used across primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, multifocal motor neuropathy, Kawasaki disease, multifocal motor neuropathy, and selected secondary immunodeficiency settings.

The immunoglobulin product market is shaped by rising diagnosis of immune disorders, broader use in neurology and hematology, and persistent supply constraints tied to human plasma collection, fractionation capacity, viral safety testing, regulatory release, and cold-chain distribution. For industry leaders, competitive advantage depends on secure plasma access, reliable manufacturing quality, patient-friendly administration options, traceability, and payer-supported evidence of clinical value.

Transformative Shifts in the Immunoglobulin Landscape

The immunoglobulin product landscape is moving from hospital-centered IVIG administration toward more flexible care models that include home infusion and SCIG self-administration. This shift is supported by clinical practice patterns that favor reduced infusion-center burden, stable serum IgG exposure, fewer systemic infusion-related reactions for some patients, and improved patient autonomy where medically appropriate.

At the same time, supply resilience has become a strategic priority. Because immunoglobulin products depend on donated human plasma and complex fractionation, short-term demand shocks cannot be solved instantly. Manufacturers and healthcare systems are investing in donor-center networks, yield optimization, manufacturing redundancy, validated quality systems, improved inventory planning, and appropriate-use protocols to protect continuity of therapy for patients who rely on these essential biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the full immunoglobulin product value chain. In plasma operations, AI-enabled analytics can improve donor scheduling, forecast collection volumes, identify operational bottlenecks, support compliance monitoring, and strengthen traceability across regulated donation networks.

In manufacturing and commercial operations, machine learning can support batch-trend analysis, deviation detection, demand forecasting, pharmacovigilance signal management, inventory allocation, and cold-chain risk prediction. The cumulative impact is not replacement of regulatory science or clinician judgment, but faster and more consistent decision support in a market where product availability, safety, traceability, and appropriate allocation are critical.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a central hub for immunoglobulin product demand and plasma supply, led by the United States with extensive plasma collection infrastructure, advanced specialty care, and strong utilization in immunology, neurology, and hematology. Canada has a more centralized blood and plasma governance model, making supply planning, national coordination, domestic collection strategy, and import dependence important policy considerations.

Europe is defined by mature regulatory oversight, broad clinical adoption, national reimbursement systems, and continuing policy focus on plasma self-sufficiency and appropriate use of IVIG and SCIG. Asia-Pacific is expanding as diagnosis rates improve in China, India, Japan, South Korea, and Australia, although access varies by reimbursement maturity, local fractionation capacity, specialist availability, regulatory pathways, and urban-rural healthcare differences.

Latin America shows growing demand in Brazil and Mexico, but availability can be uneven because of budget constraints, tender cycles, distribution complexity, and reliance on imported plasma derivatives. The Middle East, especially GCC markets, benefits from investment in tertiary care and specialty hospitals, while Africa faces the largest access gaps due to limited plasma infrastructure, affordability barriers, constrained diagnostic capacity, and uneven cold-chain reach.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining relevance as immunology and neurology services expand, but product access differs sharply between higher-income health systems and markets with limited reimbursement, specialist coverage, and plasma-derived therapy budgets. The GCC is characterized by strong hospital investment, demand for advanced biologics, and centralized procurement that can accelerate access when supply contracts, registration pathways, and logistics capacity are secure.

The European Union remains a major regulatory and demand center, with strict quality standards, pharmacovigilance requirements, national reimbursement assessment, and policy focus on plasma sufficiency. BRICS countries represent a strategically important opportunity because of large populations, rising diagnosis, and investments in domestic biomanufacturing and healthcare capacity, although pricing, reimbursement, import reliance, and access barriers remain significant.

G7 markets account for substantial global immunoglobulin consumption because they combine advanced diagnostics, established clinical guidelines, broad specialist networks, and payer coverage for approved indications. NATO countries overlap substantially with high-income systems in North America and Europe, where supply security, strategic reserves, cross-border logistics, and resilient healthcare infrastructure are increasingly important for plasma-derived medicinal products.

Key Country Insights: U.S., Canada, Mexico, Brazil, Europe, China, India, Japan, Australia & South Korea

The United States is the most influential immunoglobulin product market because of its large diagnosed patient base, strong specialty infusion ecosystem, broad payer channels, and unmatched plasma collection scale. Canada emphasizes managed access and national blood-system coordination, while Mexico is expanding specialty care but remains sensitive to pricing, reimbursement gaps, product registration, and public procurement dynamics.

Brazil leads Latin American demand, supported by a large healthcare system and growing biologics use, while the United Kingdom, Germany, France, Italy, and Spain represent established European markets with guideline-driven utilization, pharmacovigilance expectations, and payer scrutiny. Russia has demand for plasma-derived therapies but faces supply-chain, currency, procurement, and geopolitical constraints that can affect access and continuity.

China and India offer long-term growth potential as diagnosis improves, hospital capacity expands, and healthcare coverage broadens, but access remains uneven across regions and income segments. Japan, Australia, and South Korea are mature Asia-Pacific markets with high regulatory standards, strong specialty care, established blood-system oversight, and increasing emphasis on patient-centered administration models such as SCIG and home-based care where clinically suitable.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize plasma supply security by diversifying donor-center networks, strengthening long-term collection partnerships, improving donor retention, and investing in fractionation capacity and manufacturing redundancy. In a constrained market, continuity of supply is both a core commercial differentiator and a patient-safety obligation.

Organizations should also expand evidence generation for approved indications, real-world outcomes, safety monitoring, dosing patterns, switching practices, and health-economic value. Patient support programs, home-infusion partnerships, SCIG education, digital adherence tools, and clinician-facing appropriate-use resources can improve persistence while supporting payers that require proof of responsible utilization.

To improve resilience, leaders should integrate AI-enabled demand planning, cold-chain visibility, pharmacovigilance analytics, and quality-management systems without compromising regulatory oversight. Regional strategies should align product availability with reimbursement rules, tender cycles, clinical guideline adoption, and the documented needs of immunology, neurology, and hematology specialists.

Research Methodology

This executive summary is structured using a secondary research methodology grounded in publicly available regulatory, clinical, and industry intelligence sources. Relevant inputs include prescribing information, regulatory guidance from agencies such as the FDA and EMA, clinical guidelines, blood and plasma policy publications, healthcare access reports, pharmacovigilance references, and peer-reviewed literature on immunoglobulin use.

Insights were synthesized through comparative regional analysis, product-category assessment, demand-driver evaluation, supply-chain review, and healthcare access interpretation. The methodology emphasizes verified industry facts, avoids unsupported projections, and focuses on commercially actionable themes affecting immunoglobulin product access, manufacturing, reimbursement, quality assurance, and adoption.

Conclusion

Immunoglobulin products will remain essential therapies in immunology, neurology, hematology, and inflammatory disease management. Demand is supported by better diagnosis, established clinical indications, expanding care pathways, and patient preference for flexible administration, while supply remains limited by the realities of plasma collection, fractionation timelines, quality testing, and biologics manufacturing.

Market leaders that combine secure plasma sourcing, disciplined quality systems, AI-enabled operations, patient-centered commercialization, and robust evidence generation will be best positioned to compete. The future of the immunoglobulin product market will be defined by reliability, clinical evidence, equitable access, and resilient global supply chains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunoglobulin Product Market, by Product Type

  • 7.1. Hyperimmune Globulin
  • 7.2. Standard Immunoglobulin

8. Immunoglobulin Product Market, by Source

  • 8.1. Pooled Human Plasma
  • 8.2. Recombinant

9. Immunoglobulin Product Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. Immunoglobulin Product Market, by Application

  • 10.1. Hematological Disorders
    • 10.1.1. Hemolytic Anemia
    • 10.1.2. Idiopathic Thrombocytopenic Purpura
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis A
    • 10.2.2. Rubella
    • 10.2.3. Varicella
  • 10.3. Neurological Disorders
    • 10.3.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.3.2. Guillain-Barre Syndrome
    • 10.3.3. Myasthenia Gravis
  • 10.4. Primary Immune Deficiency
    • 10.4.1. Common Variable Immunodeficiency
    • 10.4.2. Severe Combined Immunodeficiency
    • 10.4.3. X-Linked Agammaglobulinemia

11. Immunoglobulin Product Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Immunoglobulin Product Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Immunoglobulin Product Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. ADMA Biologics, Inc.
  • 15.2. Bharat Serums and Vaccines Limited
  • 15.3. Bio Products Laboratory Limited
  • 15.4. Biotest AG
  • 15.5. China Biologic Products Holdings, Inc.
  • 15.6. CSL Limited
  • 15.7. Emergent BioSolutions Inc.
  • 15.8. GC Biopharma Corp.
  • 15.9. Green Cross Corporation
  • 15.10. Grifols, S.A.
  • 15.11. Hualan Biological Engineering Inc.
  • 15.12. Intas Pharmaceuticals Ltd.
  • 15.13. Kamada Ltd.
  • 15.14. Kedrion S.p.A.
  • 15.15. LFB S.A.
  • 15.16. Octapharma AG
  • 15.17. PharmaSwiss SA
  • 15.18. Prothya Biosolutions B.V.
  • 15.19. Reliance Life Sciences Pvt. Ltd.
  • 15.20. Sanquin Plasma Products B.V.
  • 15.21. Shanghai RAAS Blood Products Co., Ltd.
  • 15.22. SK Plasma Co., Ltd.
  • 15.23. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STANDARD IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STANDARD IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STANDARD IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POOLED HUMAN PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POOLED HUMAN PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POOLED HUMAN PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMOLYTIC ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMOLYTIC ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMOLYTIC ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEPATITIS A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEPATITIS A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEPATITIS A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RUBELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RUBELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RUBELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VARICELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VARICELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VARICELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRIMARY IMMUNE DEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRIMARY IMMUNE DEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRIMARY IMMUNE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMMON VARIABLE IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMMON VARIABLE IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMMON VARIABLE IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SEVERE COMBINED IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEVERE COMBINED IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SEVERE COMBINED IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL X-LINKED AGAMMAGLOBULINEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL X-LINKED AGAMMAGLOBULINEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL X-LINKED AGAMMAGLOBULINEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 145. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 198. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 207. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 216. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 217. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 246. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 249. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 294. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 298. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 306. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 307. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 315. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 317. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)